DR REDDYS LABORATORIES LTD (RDY) Form 6-K — Oct 21, 2026
Dr. Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab), combined with cisplatin and paclitaxel, as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) in India. This is the drug's second approved indication in India after nasopharyngeal carcinoma, with no PD-L1 expression requirement for patient selection. The approval is based on the Phase 3 JUPITER-06 trial, which showed a 42% reduction in risk of disease or death and median overall survival of 17.7 months versus 12.9 months with chemotherapy alone.
Key figures
- Licensed countries
- 21
- Risk reduction vs chemotherapy
- 42%
- Median overall survival chemo months
- 12.9
- Escc share of esophageal cancer india
- 80%
- Share of india cancer deaths esophageal
- 8.1%
- Median overall survival toripalimab months
- 17.7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.